Back to top
more

Atea Pharmaceuticals (AVIR)

(Delayed Data from NSDQ)

$3.77 USD

3.77
178,735

+0.20 (5.60%)

Updated Jul 22, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

bluebird (BLUE) Q4 Loss Narrower than Expected, Sales Miss

by Zacks Equity Research

bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.

Epizyme's (EPZM) Q4 Loss Wider than Expected, Sales Beat

by Zacks Equity Research

Epizyme (EPZM) incurs a wider-than-expected loss but beats sales estimates in the fourth quarter of 2020.

Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

Bionano (BNGO) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Bionano (BNGO) will provide updates on its revenues and earnings when it reports fourth-quarter and full-year 2020 results.

    Seagen (SGEN), Astellas Submit 2 sBLAs to FDA for Urothelial Cancer

    by Zacks Equity Research

    Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.

    Ocugen (OCGN) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Ocugen (OCGN) will provide updates on its pipeline when it reports fourth-quarter 2020 results.

    Kinjel Shah headshot

    4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

    by Kinjel Shah

    Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

    Aerpio (ARPO) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

    bluebird (BLUE) Down on Suspension of Sickle Cell Disease Studies

    by Zacks Equity Research

    bluebird (BLUE) temporarily suspends two studies of LentiGlobin gene therapy in SCD because of reported Suspected Unexpected Serious Adverse Reactions of acute myeloid leukemia.

    Sorrento (SRNE) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.

    Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Zoetis (ZTS) beats both earnings and sales estimates in the fourth quarter of 2020.

    What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings?

    by Zacks Equity Research

    Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.

    Myriad Genetics' (MYGN) Prolaris Test Study Outcome Favorable

    by Zacks Equity Research

    Myriad Genetics' (MYGN) new study combines a Prolaris molecular risk score approach with a clinical model for predicting a patient's benefit from androgen deprivation therapy.

    Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.

    Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates

    by Zacks Equity Research

    Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.

    Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Zoetis (ZTS) will report earnings and revenues, and provide other pipeline updates when it releases fourth-quarter 2020 results.

    Atea Pharmaceuticals (AVIR) Jumps: Stock Rises 9.5%

    by Zacks Equity Research

    Atea Pharmaceuticals (AVIR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.